Table 3.

Comparison of germline mutations identified in patients with surgically resected IPMN and ExAC controls

Germline mutation	IPMN			EXAC
	AC	AN	AF	AC	AN	AF	P value
Hereditary cancer gene	26	630	0.041	3921	105586	0.037	0.6590
Pancreatic cancer susceptibility gene	10	630	0.016	992	105732	0.009	0.1403
ATM	5	630	0.008	134	106203	0.001	<0.0001*
BRCA2	3	630	0.005	216	106188	0.002	0.2858
MSH6	1	630	0.002	261	106196	0.002	0.9709
PALB2	1	630	0.002	63	106206	0.001	0.8413
ALK	1	630	0.002	24	106209	0.000	0.3570
BRIP1	1	630	0.002	120	106202	0.001	0.7336
BUB1B	1	630	0.002	32	106209	0.000	0.4874
CDH1	1	630	0.002	9	96677	0.000	0.0861
FANCA	1	630	0.002	117	105585	0.001	0.7189
FANCD2	1	630	0.002	83	106209	0.001	0.9947
FANCI	2	630	0.003	83	106208	0.001	0.1569
FANCM	1	630	0.002	174	106183	0.002	0.9746
NBN	1	630	0.002	59	103676	0.001	0.7286
PTCH1	2	630	0.003	14	105834	0.000	<0.0001*
RB1	1	630	0.002	6	106198	0.000	0.0235
RECQL4	1	630	0.002	173	105674	0.002	0.9754
SUFU	1	630	0.002	0	105586	0.000	<0.0001*
WT1	1	630	0.002	13	105241	0.000	0.1476

IPMN - intraductal papillary mucinous neoplasm; ExAC - Exome Aggregation Consortium; AC - germline mutation allele count, AN - assessed allele number; AF - frequency of germline mutations.

^*Significant when applying Bonferroni correction for multiple testing (threshold for significance = 5.3×10⁻⁴).